Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first quarter profit
FILE - A sign for Eli Lilly & Co. sits outside their corporate headquarters in Indianapolis on April 26, 2017. , Tuesday, April 30, 2024. Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter, with strong demand for both drugs outpacing its production hikes. But the company expects its most significant increases to occur in the back half of the year.Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November.
A 26% drop in sales for Trulicity softened some of the company’s gains from Mounjaro and Zepbound. Lilly said it also dealt with supply constraints for the diabetes treatment.
Breast Cancer Inflation Diabetes Business Obesity Article 109783328
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Lilly rides Mounjaro, Zepbound to better-than-expected 1Q profit despite supply issuesRapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first quarter profit. The drugmaker also hiked its forecast for 2024 well beyond analyst expectations after sales of Mounjaro more than tripled in the year’s first quarter.
Lire la suite »
Lilly rides Mounjaro, Zepbound to better-than-expected 1Q profit despite supply issuesRapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first quarter profit.
Lire la suite »
Lilly rides Mounjaro, Zepbound to better-than-expected 1Q profit despite supply issuesRapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first quarter profit.
Lire la suite »
Most doses of Eli Lilly's Zepbound, Mounjaro in short supply through June, FDA saysThe insatiable demand for weight loss and diabetes drugs is still trouncing supply, even as Eli Lilly and Novo Nordisk work to increase production capacity.
Lire la suite »
Most of Lilly's Mounjaro and Zepbound doses in limited supply, FDA saysMost doses of Eli Lilly's diabetes drug Mounjaro and weight-loss drug Zepbound would be in limited supply through the second quarter of this year due to increased demand, the U.S. Food and Drug Administration's website showed on Wednesday.
Lire la suite »
Eli Lilly beats on quarterly profit, hikes full-year guidance on strong sales of Zepbound, MounjaroZepbound reported $517.4 million in sales for the quarter, even as most doses of the drug slipped into shortages in the U.S.
Lire la suite »